SCHEMBL13804185

SCHEMBL13804185

CNc1cc2ccccc2c(-c2ccccc2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 4/20 0.53
BPTF Q12830 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
MAPT P10636 3/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ADORA2A P29274 2/20 0.41
ADORA1 P30542 1/20 0.40
NCF1 P14598 1/20 0.40
PDE10A Q9Y233 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
RECQL P46063 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13804182 0.76 CYP2A6 (0.44) NUDT1BPTFKDM4EALDH1A1GAA
SCHEMBL10671008 0.76 PDE10A (0.47) NUDT1TDP1MAPTKDM4EALDH1A1
SCHEMBL3972143 0.75 AURKA (0.56)
SCHEMBL21786398 0.74 NCF1 (0.42) NUDT1BPTFTDP1KDM4EALDH1A1
SCHEMBL13804174 0.74 NCF1 (0.42) NUDT1BPTFTDP1MAPTALDH1A1
SCHEMBL3318116 0.73 KDM4E (0.53) NUDT1MAPTKDM4EALDH1A1MEN1
SCHEMBL29446790 0.73 KDM4E (0.53) NUDT1MAPTKDM4EALDH1A1MEN1
SCHEMBL30616770 0.73 KDM4E (0.53) NUDT1MAPTKDM4EALDH1A1MEN1
SCHEMBL23735857 0.73 NCF1 (0.41) NUDT1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL25847342 0.73 HPGDS (0.44) NUDT1TDP1MAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9522145-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-12-20 US disclosed
US-20150190390-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED 2015-07-09 US disclosed
US-9012473-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-04-21 US disclosed
US-20140206689-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-07-24 US disclosed
US-8722704-B2 Modulators of ATP-binding cassette-transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-05-13 US disclosed
US-20130296364-A1 MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-11-07 US disclosed
US-8507524-B2 Modulators of ATP-binding cassette-transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-08-13 US disclosed
US-20090143381-A1 MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150190390-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCC2 NUDT1 570/4885BPTF 436/4885TDP1 4384/4885
US-20130296364-A1 MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS CFTR, ABCB1, ABCC2 NUDT1 549/4885BPTF 448/4885TDP1 4358/4885
US-20090143381-A1 MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS CFTR, ABCB1, ABCC2 NUDT1 549/4885BPTF 448/4885TDP1 4358/4885
US-20140206689-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCC2 NUDT1 474/4885BPTF 442/4885TDP1 4242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.